VistaGen Price Earnings To Growth Ratio from 2010 to 2024

VTGN Stock  USD 4.10  0.16  3.76%   
VistaGen Therapeutics Price Earnings To Growth Ratio yearly trend continues to be very stable with very little volatility. Price Earnings To Growth Ratio is likely to drop to 51.15. During the period from 2010 to 2024, VistaGen Therapeutics Price Earnings To Growth Ratio quarterly data regression pattern had range of 9 K and standard deviation of  2,323. View All Fundamentals
 
Price Earnings To Growth Ratio  
First Reported
2010-12-31
Previous Quarter
53.8469825
Current Value
51.15
Quarterly Volatility
2.3 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check VistaGen Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among VistaGen main balance sheet or income statement drivers, such as Interest Expense of 25.1 K, Selling General Administrative of 12.5 M or Other Operating Expenses of 71.3 M, as well as many exotic indicators such as Dividend Yield of 1.0E-4, Average Payables of 0.0 or ROIC of 20.05. VistaGen financial statements analysis is a perfect complement when working with VistaGen Therapeutics Valuation or Volatility modules.
  
This module can also supplement VistaGen Therapeutics' financial leverage analysis and stock options assessment as well as various VistaGen Therapeutics Technical models . Check out the analysis of VistaGen Therapeutics Correlation against competitors.
To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.

Latest VistaGen Therapeutics' Price Earnings To Growth Ratio Growth Pattern

Below is the plot of the Price Earnings To Growth Ratio of VistaGen Therapeutics over the last few years. It is VistaGen Therapeutics' Price Earnings To Growth Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in VistaGen Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Price Earnings To Growth Ratio10 Years Trend
Very volatile
   Price Earnings To Growth Ratio   
       Timeline  

VistaGen Price Earnings To Growth Ratio Regression Statistics

Arithmetic Mean607.31
Coefficient Of Variation382.52
Mean Deviation1,120
Median0.02
Standard Deviation2,323
Sample Variance5.4M
Range9K
R-Value0
Mean Square Error5.8M
R-Squared0.000022
Significance0.99
Slope2.43
Total Sum of Squares75.6M

VistaGen Price Earnings To Growth Ratio History

2024 51.15
2023 53.85
2022 -0.0241
2021 -0.32
2018 0.18
2017 9004.47
2016 0.0152

About VistaGen Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include VistaGen Therapeutics income statement, its balance sheet, and the statement of cash flows. VistaGen Therapeutics investors use historical funamental indicators, such as VistaGen Therapeutics's Price Earnings To Growth Ratio, to determine how well the company is positioned to perform in the future. Although VistaGen Therapeutics investors may use each financial statement separately, they are all related. The changes in VistaGen Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on VistaGen Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on VistaGen Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in VistaGen Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price Earnings To Growth Ratio 53.85  51.15 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether VistaGen Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of VistaGen Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vistagen Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vistagen Therapeutics Stock:
Check out the analysis of VistaGen Therapeutics Correlation against competitors.
To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.
Note that the VistaGen Therapeutics information on this page should be used as a complementary analysis to other VistaGen Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for VistaGen Stock analysis

When running VistaGen Therapeutics' price analysis, check to measure VistaGen Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VistaGen Therapeutics is operating at the current time. Most of VistaGen Therapeutics' value examination focuses on studying past and present price action to predict the probability of VistaGen Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VistaGen Therapeutics' price. Additionally, you may evaluate how the addition of VistaGen Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Is VistaGen Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.96)
Revenue Per Share
0.077
Quarterly Revenue Growth
1.291
Return On Assets
(0.26)
Return On Equity
(0.45)
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.